Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bougainvillea in the preparation of drugs for preventing and/or treating amphetamine drug addiction-related diseases

A kind of technology of amphetamines and related diseases, applied in the field of medicine, can solve problems such as no drugs yet

Active Publication Date: 2022-07-22
BEIJING UNION PHARMA FACTORY
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the detoxification drugs approved for marketing at home and abroad, such as methadone and naloxone, are all substitutes for opioid drugs, and there is no drug that can effectively treat the addiction caused by amphetamine-type stimulants.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bougainvillea in the preparation of drugs for preventing and/or treating amphetamine drug addiction-related diseases
  • Application of bougainvillea in the preparation of drugs for preventing and/or treating amphetamine drug addiction-related diseases
  • Application of bougainvillea in the preparation of drugs for preventing and/or treating amphetamine drug addiction-related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1: The effect of Bugfuran itself on the excitability of mice.

[0042] Mice were first arranged to acclimate in the behavior box for 3 days, 4 hours per day. Test on the fourth day. During the test, the mice were first allowed to move freely in the behavior box for 30 minutes, and then the animals were injected intraperitoneally with Bugfuran, and then the animals were re-inserted into the behavior box and recorded for 1 hour. The specific dosing is as follows:

[0043] 1) Blank group (10% Tween 80 in physiological saline solution, 2.5 mL / kg, intraperitoneal injection) n=12

[0044] 2) AF1 (Bugfuran dissolved in physiological saline solution containing 10% Tween 80, dose 1 mg / kg, intraperitoneal injection) n=5

[0045] 3) AF10 (Bugfuran dissolved in physiological saline solution containing 10% Tween 80, dose 10mg / kg, intraperitoneal injection) n=5

[0046] 4) AF50 (Bugfuran dissolved in physiological saline solution containing 10% Tween 80, dose 50mg / kg, int...

Embodiment 2

[0048] Example 2: CPP training - environmental adaptation and the effect of drugs on animal body weight

[0049] Mice were subjected to CPP training, as previously described, for a total of 4 days, twice a day, 20 min each time, with 4 hr intervals in between. The first experiment was administered with normal saline and placed in the saline compartment, and the second experiment was administered with drugs (buguefuran, amphetamine or combined administration) and placed in the administration compartment. The specific dosing is as follows:

[0050] 1) Blank group (0.9% saline, 2.5mL / kg, intraperitoneal injection) n=13

[0051] 2) AF5 (Bugfuran dissolved in physiological saline solution containing 10% Tween 80, dose 5mg / kg, intraperitoneal injection) n=6

[0052] 3) AF20 (Bugfuran dissolved in physiological saline solution containing 10% Tween 80, dose 20mg / kg, intraperitoneal injection) n=9

[0053] 4) AF5+AMPH (5mg / kg Bugufuran+1mg / kg amphetamine, intraperitoneal injection) ...

Embodiment 3

[0057] Example 3: Effect of Bugfuran on CPP Formation and Amphetamine-induced CPP Formation

[0058] Bugfuran was administered to mice alone to evaluate the effect of bugfuran itself on CPP formation; a mixed solution of bugfuran and amphetamine was administered to mice to evaluate the effect of bugfuran on amphetamine-induced CPP formation. The CPP formation test was performed after completing the CPP training. On the test day, the mice were placed freely in the shuttle box, recorded for 20 minutes and the dwell time of the animals in each compartment was counted. The specific dosing is as follows:

[0059] 1) Blank group (0.9% saline, 2.5mL / kg, intraperitoneal injection, n=13)

[0060] 2) AF5 (Bugfuran dissolved in physiological saline solution containing 10% Tween 80, dose 5mg / kg, intraperitoneal injection) n=6

[0061] 3) AF20 (Bugfuran dissolved in physiological saline solution containing 10% Tween 80, dose 20mg / kg, intraperitoneal injection) n=9

[0062] 4) AF5+AMPH ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of bougainvillea for preventing and / or treating the addiction of amphetamine drugs. Described amphetamine drugs include but are not limited to amphetamine, methamphetamine, fenfluramine, phentermine, amphetamine sulfate, methamphetamine, tiamphetamine, dimethylphenethylamine or the pharmaceutically acceptable substances of the above-mentioned substances. one or more of the salts.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of bougainvillea in the preparation of medicines for preventing and / or treating amphetamine-type drug addiction-related diseases. Background technique [0002] Amphetamine-type stimulants are the most common illegal drugs of abuse at present, which can be divided into three categories: (1) traditional amphetamine-type stimulants, mainly represented by amphetamine and methamphetamine; amphetamine is amphetamine (AMPH), which is the central Stimulant, addictive. Methamphetamine hydrochloride is "ice", and its effect lasts longer than opioids such as morphine and heroin, and is more harmful. (2) Weight-loss amphetamine stimulants, the main representative drugs are fenfluramine, phentermine and amphetamine sulfate. (3) Hallucinogenic amphetamine stimulants, the main representative drugs are methamphetamine (MDMA), titamphetamine (MDA), dimethylphenethylamine (MDE...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/352A61K31/343A61K31/138A61K31/4525A61K31/135A61K31/495A61K31/5513A61K31/4515A61P25/30A61P25/36A61P25/20A61P25/24
CPCA61K31/352A61K31/343A61K31/138A61K31/4525A61K31/135A61K31/495A61K31/5513A61K31/4515A61P25/30A61P25/36A61P25/20A61P25/24A61K2300/00
Inventor 汪小涧董梁
Owner BEIJING UNION PHARMA FACTORY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com